Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has issued an announcement.
Eupraxia Pharmaceuticals has filed a preliminary prospectus supplement to launch a proposed public offering of common shares, or pre-funded warrants, in Canada and the U.S., with Cantor and LifeSci Capital as joint bookrunners and Bloom Burton as co-manager. The size, pricing and timing remain subject to market conditions, regulatory approvals, and stock exchange listing requirements.
The company plans to deploy the net proceeds to advance its EP-104GI program for Eosinophilic Esophagitis through Phase 2 and Phase 3 preparation, expand studies into other gastrointestinal indications such as esophageal strictures and fibrostenotic Crohn’s disease, and fund additional R&D, business development, and corporate infrastructure. The financing aims to accelerate Eupraxia’s late-stage pipeline and commercial readiness, potentially strengthening its position in the GI-focused biotech space and supporting future growth initiatives.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on TSE:EPRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:EPRX is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses and cash burn), partially offset by a conservatively levered balance sheet. Technicals are the main positive, showing a clear uptrend and constructive momentum, while valuation is constrained by negative earnings and no dividend data.
To see Spark’s full report on TSE:EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on locally delivered, extended-release therapeutics targeting diseases with significant unmet medical need. Its proprietary Diffusphere micro-sphere technology is designed to enable controlled, targeted delivery of both existing and novel drugs, with a growing emphasis on gastrointestinal indications.
Average Trading Volume: 78,806
Technical Sentiment Signal: Buy
Current Market Cap: C$587.9M
Find detailed analytics on EPRX stock on TipRanks’ Stock Analysis page.